Program
BIO VentureForum East 2007 Program
(as of June 8, 2007)
| Monday, June 18, 2007 | ||
| 8:00 a.m. – 5:00 p.m. | Executive Presentation Workshop (hosted by Gowling Lafleur Henderson LLP) Open to all, but space is limited and all must preregister. Free to presenting companies, $295/$495 for others | Maisonneuve D |
| 4:00 p.m. – 7:00 p.m. | Registration Open | Neufchatel (in lobby) |
| 6:00 p.m. – 7:30 p.m. | Welcome Reception | Maisonneuve A & B |
| Tuesday, June 19, 2007 | ||
| 7:00 a.m. – 6:00 p.m. | Registration Open | Neufchatel (in lobby) |
| 7:30 a.m. – 8:00 a.m. | Breakfast | Salon de Bal |
| 8:00 a.m. – 8:15 a.m. | WELCOMING REMARKS: James C. Greenwood, President and CEO, Biotechnology Industry Organization |
Salon de Bal |
| 8:15 a.m. – 9:10 a.m. | Plenary Session: M&A: Is it the new IPO? This session will be a case study of recent deals, including Merck/Sirna and Genzyme/Anormed. Panelists will touch upon a few topics, including: Is acquisition a better liquidity option for VCs? What do firms being acquired have to do to position themselves? | Salon de Bal |
| • MODERATOR: Simon Gill, Co-Head of Healthcare Investment Banking, RBC Capital Markets Corporation • Ken Galbreith, Venture Partner, VenturesWest, former chairman of AnorMED (acquired by Genzyme Corp.) • Reid J. Leonard, PhD, Executive Director, Licensing & External Research, Merck Research Laboratories • Bharat M. Chowrira, PhD, JD, Executive Director, Worldwide Licensing & External Research, Merck and Co., Inc. |
||
| 9:15 a.m. – 9:30 a.m. | Networking Break | Foyer |
| 9:30 a.m. – 12:00 p.m. | Company Presentations | Viger A, B & C |
| 9:30 a.m. – 12:00 p.m. | One on One meetings | One on One Suites |
| 11:00 a.m. – 12:00 p.m. | Workshop: Cross Border Deals with US and Canadian VCs Small private companies from both sides of the border can no longer expect to be financed only by local investors. More and more, these companies are reaching out across the border to attract capital. And increasingly, investors are interested in early-stage companies located a flight away. In this manner, Canadian companies have started increasingly tapping into American VC pockets, and likewise, American companies are looking north for VC funds. Whether this involves directly investing into the foreign entity or investing through an exchangeable share structure, these deals are increasing in popularity. How does a company tap into a foreign VC market? Once one foreign investor has been attracted, how easy is it to attract more? How does this foreign capital influence the development of internal strategy? Does it influence the exit? Does the arrival of an important foreign investor necessarily mean moving the company? Are exchangeable share structures as complex as they first sound? What could be done to improve the ease of capital flow across our border? | Viger C |
| • MODERATOR: Geoffrey K. Taber, Partner, Osler, Hoskin & Harcourt LLP • Elizabeth Douville, PhD, Vice President, AgeChem Venture Fund, GeneChem Management, Inc. • David J. Drutz, General Partner, Pacific Rim Ventures Co., Ltd • Vipin K. Garg, President and Chief Executive Officer, Tranzyme Pharma • Stephen F. Keane, Senior Vice President, Corporate Development, Ambit Biosciences |
||
| 12:00 p.m. – 1:30 p.m. | Luncheon with Keynote Speaker: John Maraganore, Ph.D. President and Chief Executive Officer, Alnylam Pharmaceuticals "Building Innovative Biotech Companies" |
Salon de Bal |
| 1:30p.m. – 1:45 p.m. | Networking Break | Foyer |
| 1:45 p.m. – 3:15 p.m. | Company Presentations | Viger A & B |
| 1:45 p.m. – 5:45 p.m. | One on One meetings | One on One Suites |
| 2:15 p.m. – 3:15 p.m. | Workshop: Seeking Non-Dilutive Capital? Navigating the SBIR Program.For earlier stage US based companies, funding sources like the US government’s Small Business Innovation Research grant program are vital to their survival. Learn from the director of the SBIR program at the NIH how your firm can better take advantage of this important funding resource. Included in the discussion will be an overview of new funding opportunities from the NIH, and advice from a successful grantee that now has products on the market. |
Viger C |
| • Andrew J. Kurtz, PhD, Program Manager, Small Business Innovation Research Program, National Cancer Institute • Thomas R. Mackie, PhD, Co-founder, Chairman of the Board and Director of Research, TomoTherapy Incorporated |
||
| 3:15 p.m. – 3:30 p.m. | Break | Foyer |
| 3:30 p.m. – 5:45 p.m. | Company Presentations | Viger A & B |
| 3:30 p.m. – 4:30 p.m. | Workshop: Beyond Seed Funding: What a CEO Needs to Know About Creating Value to Attract Capital? | Viger C |
• MODERATOR: Alan F. Eisenberg, Executive Vice President for Emerging Companies and Business Development, Biotechnology Industry Organization |
||
| 5:45 p.m. – 6:15 p.m. | Buses depart for Gala Reception | Main Lobby |
| 6:00 p.m. – 8:30 p.m. | Gala Reception (offsite) | Holder Restaurant |
|
||
| Wednesday, June 20, 2007 | ||
| 7:00 a.m. – 3:30 p.m. | Registration Open | Neufchatel (in lobby) |
| 7:30 a.m. – 8:30 a.m. | Breakfast | Salon de Bal |
| 8:15 a.m. – 9:10 a.m. | Plenary Session : Rules of Engagement: Best Practices for Working with the FDA Building a strong working relationship with the FDA, and understanding its requirements and how it approaches regulatory decisions are important dimensions to securing timely agency reviews and to achieving marketing approval. Navigating FDA can be a challenge for small companies, who may be going through the process organizationally for the first time and developing first in class products for complex diseases. A recent survey by Booz Allen found approvals after one review cycle were significantly lower for small U.S. biotech and foreign companies compared with their larger counterparts. This session will provide perspectives on best practices for engaging FDA at key points in the product development cycle from ex-FDA officials and industry experts. What are the goals and expectations, on the part of the company and the FDA at key meetings? What kinds of agreements flow from key meetings? What are common pitfalls and strategies for avoiding them? |
Salon de Bal |
| • MODERATOR: Ramsey Baghdadi, Managing Editor, The RPM Report • Wilson Bryan, MD, Senior Clinical Consultant, Biologics Consulting Group • Thomas Q. Garvey, III, MD, President, Garvey Associates, Inc • Ulrich Grau, President & CEO, Lux Biosciences |
||
| 9:15 a.m. – 9:30 a.m. | Networking Break | Foyer |
| 9:30 a.m. – 10:30 a.m. | Pharma/Large Cap Biotech Presentations | Viger A & B |
| 10:30 a.m. – 12:00 p.m. | One on One meetings | One on One Suites |
| 10:30 a.m. – 12:00 p.m. | Company Presentations | Viger A & B |
| 11:00 a.m. – 12:00 p.m. | Workshop: Financing Success Stories Over the past year, venture funding, specifically in the healthcare sector, has been hot. Companies have raised hundreds of millions of dollars and are using the funding to develop important products that may improve the lives of millions. This panel will examine some of the most successful raises over the past year, and will address why companies thought they were successful in their raise, lessons learned, and “war stories” that occurred along the way. The panel will include CEOs from companies that recently raised funds as well as VCs that played a role in raising these funds. | Viger C |
• MODERATOR: Janice T. Bourque, Senior Vice President & Group Head-Life Sciences, Comerica Bank |
||
| 12:00 p.m. – 1:30 p.m. | Luncheon with Keynote Speaker: Stephen Sands, Lazard "Biotech at the Crossroads: Top 10 M&A, Alliance and Equity Trends" | Salon de Bal |
| 1:30p.m. – 1:45 p.m. | Networking Break | Foyer |
| 1:30 p.m. – 2:30 p.m. | One on One meetings | One on One Suites |
| 1:45 p.m. – 2:30 p.m. | Company Presentations | Viger A & B |
| 2:30 p.m. – 3:30 p.m. followed by Closing Reception | Closing Plenary and reception: Is the Traditional VC Model Broken? These days, VCs are finding it harder and harder to identify exit strategies that will provide its investors with significant returns. Because of this, some VCs have stopped raising new funds, have changed their investment strategy or are looking for new ways to provide returns to its investors, while some VCs are continuing to follow the traditional VC model in hopes of making the right investments in the right companies and providing returns that way. This panel will examine if VCs truly think the traditional VC model is broken and will include VCs with different opinions on the topic. | Salon de Bal |
• MODERATOR: Sara Jane Demy, Vice President, Business Development and Investor Relations, Biotechnology Industry Organization |
||